Aegle Therapeutics is developing a first in class therapy using extracellular vesicles, including exosomes, secreted by allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions including dystrophic epidermolysis bullosa, a rare pediatric blistering disease.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.